Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection

Table 3 Adverse events in the patients of the four groups n (%)

Adverse events	Group 1 (n = 180)	Group 2 (n = 180)	Group 3 (n = 180)	Group 4 (n = 180)
Dizziness	5 (2.8)	4 (2.2)	6 (3.3)	7 (3.9)
Vomiting	3 (1.7)	4 (2.2)	4 (2.2)	3 (1.7)
Diarrhea	1 (0.6)	4 (2.2)	2 (1.1)	3 (1.7)
Nausea	3 (1.7)	0 (0)	0 (0)	1 (0.6)
Skin rash and itchy skin	1 (0.6)	1 (0.6)	0 (0)	2 (1.1)
Asthenia	2 (1.1)	3 (1.7)	3 (1.7)	1 (0.6)
Total	15 (8.3)	16 (8.9)	15 (8.3)	17 (9.4)

Patients in Group 1 and Group 3 received rabeprazole (10 mg), amoxicillin (1000 mg) and furazolidone (100 mg) twice daily for 7 and 10 d, respectively and patients in Group 2 and Group 4 received rabeprazole (10 mg), bismuth (220 mg), amoxicillin (1000 mg) and furazolidone (100 mg) twice daily for 7 and 10 d, respectively. Treatment was discontinued for 18 patients who experienced vomiting, skin rash and itchy skin.